Identification

Name
Atorvastatin
Accession Number
DB01076  (APRD00055)
Type
Small Molecule
Groups
Approved
Description

Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.

Structure
Thumb
Synonyms
  • Lipovastatinklonal
Product Ingredients
IngredientUNIICASInChI Key
Atorvastatin CalciumC0GEJ5QCSO134523-03-8FQCKMBLVYCEXJB-MNSAWQCASA-L
Atorvastatin calcium trihydrate48A5M73Z4Q344423-98-9SHZPNDRIDUBNMH-NIJVSVLQSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-atorvastatin CalciumTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet80 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
AtorvastatinTablet40 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet40 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet80 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet80 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet80 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atorvastatinTablet20 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet80 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet10 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet40 mgOralApotex Corporation2010-05-19Not applicableCanada
Atorvastatin CalciumTablet, film coated10 mg/1OralMajor2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAv Kare, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralNu Care Pharmaceuticals,inc.2016-08-04Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAidarex Pharmaceuticals LLC2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralGolden State Medical Supply2012-05-29Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atorvastatin CalciumTablet, film coated40 mg/1OralCipla Limited2017-11-16Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralDirectrx2017-11-10Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralSciegen Pharmaceuticals Inc.2016-05-19Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralRemedy Repack2017-11-15Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralSt. Marys Medical Park Pharmacy2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralRemedy Repack2017-11-01Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralNu Care Pharmaceuticals,inc.2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralSciegen Pharmaceuticals Inc.2016-05-19Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCipla Limited2017-11-16Not applicableUs
International/Other Brands
Atogal (Ingers (Czech Republic)) / Cardyl (Pfizer (Spain)) / Faboxim (Fabop (Argentina)) / Hipolixan (Pasteur (Chile)) / Lipotropic (Drugtech (Chile)) / Liprimar (Pfizer (Hungary, Ukraine), Goedecke (Russia)) / Lowden (Saval (Chile)) / Normalip (Quesada (Argentina)) / Sincol (Indeco (Argentina)) / Sortis (Pfizer (Austria, Czech Republic, Germany, Hungary, Poland, Portugal, Switzerland), Godecke (Germany), Parke, Davis (Germany)) / Torvacard (Zentiva (Czech Republic, Hungary, Poland, Russia, Ukraine)) / Torvast (Pfizer (Italy)) / Totalip (Guidotti (Italy)) / Tulip (Lek (Czech Republic, Russia), Wermar (Mexico), Sandoz (Poland, Ukraine), Pharmacia (Spain)) / Vastina (Penn (Argentina)) / Xanator (Sieger (Greece)) / Xarator (Parke, Davis (Italy)) / Zurinel (Prater (Chile))
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Amlodipine besylate and atorvastatin calciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2014-09-03Not applicableUs
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-06Not applicableUs
Amlodipine besylate and atorvastatin calciumAtorvastatin calcium trihydrate (40 mg/1) + Amlodipine besylate (2.5 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2013-02-14Not applicableUs
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (80 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-06Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin Calcium (40 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralDr Reddy's Laboratories2014-03-17Not applicableUs43598 0316 30 nlmimage10 f63ffb6f
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralGreenstone, Llc2014-04-04Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin Calcium (10 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralDr Reddy's Laboratories2014-03-17Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium trihydrate (20 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralGreenstone, Llc2014-04-04Not applicableUs
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (80 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-06Not applicableUs
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin Calcium (80 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2012-03-08Not applicableUs
Categories
UNII
A0JWA85V8F
CAS number
134523-00-5
Weight
Average: 558.6398
Monoisotopic: 558.253000445
Chemical Formula
C33H35FN2O5
InChI Key
XUKUURHRXDUEBC-KAYWLYCHSA-N
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
IUPAC Name
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[[email protected]@H](O)C[[email protected]@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1

Pharmacology

Indication

May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.

Structured Indications
Pharmacodynamics

Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.

Mechanism of action

Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
NDipeptidyl peptidase 4
inhibitor
Human
UAryl hydrocarbon receptor
agonist
Human
Absorption

Atorvastatin is rapidly absorbed after oral administration with maximum plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-pass metabolism in the liver.

Volume of distribution

381 L

Protein binding

>98% bound to plasma proteins

Metabolism

Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. CYP3A4 is also involved in the metabolism of atorvastatin.

Route of elimination

Eliminated primarily in bile after hepatic and/or extrahepatic metabolism. Does not appear to undergo significant enterohepatic recirculation. Less than 2% of the orally administered dose is recovered in urine.

Half life

14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites

Clearance
Not Available
Toxicity

Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose atorvastatin.Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T AlleleEffect Directly StudiedPatients with this genotype have a lesser reduction in LDL cholesterol with atorvastatin.Details
Cytochrome P450 3A4CYP3A4*1B(G;G) / (A;G)A > GEffect Directly StudiedPatients with this genotype have an greater reduction in LDL cholesterol with atorvastatin.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Atorvastatin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Atorvastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Atorvastatin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Atorvastatin.Investigational
AbirateroneThe serum concentration of Atorvastatin can be increased when it is combined with Abiraterone.Approved
AcenocoumarolAtorvastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Atorvastatin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin.Approved, Vet Approved
AcetohexamideAtorvastatin may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atorvastatin.Approved
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Atorvastatin.Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atorvastatin.Approved
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Atorvastatin.Approved, Investigational
AlmasilateThe serum concentration of Atorvastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AlogliptinThe serum concentration of Atorvastatin can be increased when it is combined with Alogliptin.Approved
AloglutamolThe serum concentration of Atorvastatin can be decreased when it is combined with Aloglutamol.Experimental
Alpha-1-proteinase inhibitorThe serum concentration of Atorvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Atorvastatin.Approved, Illicit, Investigational
AluminiumThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbroxolThe risk or severity of adverse effects can be increased when Ambroxol is combined with Atorvastatin.Approved, Investigational
AmiodaroneThe metabolism of Atorvastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Atorvastatin.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Atorvastatin.Approved, Investigational
AmprenavirThe serum concentration of Atorvastatin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Atorvastatin.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Anastrozole is combined with Atorvastatin.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Atorvastatin.Approved
Antithrombin III humanThe serum concentration of Atorvastatin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Atorvastatin can be increased when it is combined with Apixaban.Approved
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Atorvastatin.Approved, Investigational
AprotininThe serum concentration of Atorvastatin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Atorvastatin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Atorvastatin.Approved, Investigational
AstemizoleThe risk or severity of adverse effects can be increased when Astemizole is combined with Atorvastatin.Approved, Withdrawn
AsunaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Atorvastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Atorvastatin.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Atorvastatin.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Atorvastatin.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Atorvastatin.Investigational
AzithromycinAzithromycin may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Atorvastatin.Approved
BatimastatThe serum concentration of Atorvastatin can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Atorvastatin can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Atorvastatin.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Atorvastatin.Approved, Investigational
BenzamidineThe serum concentration of Atorvastatin can be increased when it is combined with Benzamidine.Experimental
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Atorvastatin.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Atorvastatin.Approved, Vet Approved
BexaroteneThe serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Bicalutamide is combined with Atorvastatin.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Atorvastatin.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
BivalirudinThe serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Atorvastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Atorvastatin.Approved, Investigational
BosentanThe metabolism of Atorvastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atorvastatin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atorvastatin.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Atorvastatin.Approved, Illicit, Investigational, Vet Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Atorvastatin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Atorvastatin.Approved
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Atorvastatin.Approved
Calcium CarbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Atorvastatin can be decreased when it is combined with Calcium silicate.Experimental
CamostatThe serum concentration of Atorvastatin can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Capsaicin is combined with Atorvastatin.Approved
CaptoprilThe serum concentration of Atorvastatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Atorvastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Atorvastatin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Atorvastatin.Investigational
CarbutamideAtorvastatin may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Atorvastatin.Experimental
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Atorvastatin.Approved
CelecoxibThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Atorvastatin.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Cerivastatin is combined with Atorvastatin.Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Atorvastatin.Approved, Vet Approved
ChlorpropamideAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Atorvastatin.Approved
CholesterolThe serum concentration of Atorvastatin can be increased when it is combined with Cholesterol.Experimental, Investigational
CholestyramineThe serum concentration of Atorvastatin can be decreased when it is combined with Cholestyramine.Approved
ChymostatinThe serum concentration of Atorvastatin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Atorvastatin can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Atorvastatin.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atorvastatin.Approved
CimetidineThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cimetidine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Atorvastatin.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Atorvastatin.Approved, Investigational
CiprofloxacinThe risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Atorvastatin.Approved, Investigational
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Atorvastatin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Atorvastatin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Atorvastatin.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Atorvastatin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Clofazimine is combined with Atorvastatin.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Clomifene is combined with Atorvastatin.Approved, Investigational
ClorindioneAtorvastatin may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Atorvastatin.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Atorvastatin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Atorvastatin.Approved
CobicistatThe serum concentration of Atorvastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Atorvastatin.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
ColesevelamThe serum concentration of Atorvastatin can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Atorvastatin can be decreased when it is combined with Colestipol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Atorvastatin.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Atorvastatin.Approved
CrisaboroleThe metabolism of Atorvastatin can be decreased when combined with Crisaborole.Approved
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Atorvastatin.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Atorvastatin.Approved, Investigational
CyclosporineThe serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Atorvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Atorvastatin.Approved
DabrafenibThe serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Atorvastatin can be increased when it is combined with Daclatasvir.Approved
DalfopristinThe risk or severity of adverse effects can be increased when Dalfopristin is combined with Atorvastatin.Approved
DanazolThe serum concentration of Atorvastatin can be increased when it is combined with Danazol.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.Approved, Investigational
DarexabanThe serum concentration of Atorvastatin can be increased when it is combined with Darexaban.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Atorvastatin.Experimental
DarunavirThe serum concentration of Atorvastatin can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Atorvastatin can be increased when it is combined with Dasabuvir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Atorvastatin.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Atorvastatin.Approved
DeferasiroxThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Atorvastatin can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Atorvastatin can be increased when it is combined with Delapril.Experimental
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Atorvastatin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Atorvastatin.Approved, Investigational, Vet Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Atorvastatin.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Atorvastatin.Approved, Illicit, Vet Approved
DicoumarolAtorvastatin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Atorvastatin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Atorvastatin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atorvastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atorvastatin.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Atorvastatin.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Atorvastatin.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Atorvastatin.Approved
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin.Approved, Vet Approved
DiphenadioneAtorvastatin may increase the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Atorvastatin.Approved, Investigational
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Atorvastatin.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atorvastatin.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Atorvastatin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Atorvastatin.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Atorvastatin can be increased when it is combined with Dronedarone.Approved
EcabetThe serum concentration of Atorvastatin can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Atorvastatin.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.Approved
EfavirenzThe serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Atorvastatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Atorvastatin.Approved, Investigational
ElafinThe serum concentration of Atorvastatin can be increased when it is combined with Elafin.Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Elbasvir is combined with Atorvastatin.Approved
EltrombopagThe serum concentration of Atorvastatin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Atorvastatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Atorvastatin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Atorvastatin can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe risk or severity of adverse effects can be increased when Enasidenib is combined with Atorvastatin.Approved
EnzalutamideThe serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Atorvastatin.Approved, Investigational
Epigallocatechin GallateThe serum concentration of Atorvastatin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Atorvastatin.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Atorvastatin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Atorvastatin.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Atorvastatin.Approved
ErythromycinThe serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Atorvastatin.Approved
Ethyl biscoumacetateAtorvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Atorvastatin.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Atorvastatin.Approved, Investigational
EtravirineThe serum concentration of Atorvastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Ezetimibe is combined with Atorvastatin.Approved
FaldaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Atorvastatin.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Atorvastatin.Withdrawn
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Atorvastatin.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Atorvastatin.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Atorvastatin.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.Approved
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Atorvastatin.Approved
FluconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Fluconazole.Approved
FluindioneAtorvastatin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Atorvastatin.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Atorvastatin.Approved, Vet Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atorvastatin.Approved
FluvastatinThe risk or severity of adverse effects can be increased when Fluvastatin is combined with Atorvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Atorvastatin.Approved, Investigational
FosamprenavirThe serum concentration of Atorvastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe risk or severity of adverse effects can be increased when Fosaprepitant is combined with Atorvastatin.Approved
FosinoprilThe serum concentration of Atorvastatin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Atorvastatin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Atorvastatin.Approved, Investigational
GabexateThe serum concentration of Atorvastatin can be increased when it is combined with Gabexate.Investigational
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Atorvastatin.Investigational
GeldanamycinThe serum concentration of Atorvastatin can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
GlibornurideAtorvastatin may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideAtorvastatin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAtorvastatin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAtorvastatin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAtorvastatin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAtorvastatin may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideThe risk or severity of adverse effects can be increased when Glyburide is combined with Atorvastatin.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Glycerol Phenylbutyrate is combined with Atorvastatin.Approved
GM6001The serum concentration of Atorvastatin can be increased when it is combined with GM6001.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Atorvastatin.Approved
HistamineThe risk or severity of adverse effects can be increased when Histamine is combined with Atorvastatin.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Atorvastatin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin.Approved, Vet Approved
HydrotalciteThe serum concentration of Atorvastatin can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Atorvastatin.Approved
IdraparinuxThe serum concentration of Atorvastatin can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Atorvastatin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Atorvastatin.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Atorvastatin.Approved
ImidaprilThe serum concentration of Atorvastatin can be increased when it is combined with Imidapril.Investigational
IndinavirThe serum concentration of Atorvastatin can be increased when it is combined with Indinavir.Approved
indisulamThe risk or severity of adverse effects can be increased when indisulam is combined with Atorvastatin.Investigational
Insulin HumanAtorvastatin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAtorvastatin may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Atorvastatin.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Atorvastatin.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Atorvastatin.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Atorvastatin.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Atorvastatin.Approved
IsoflurophateThe serum concentration of Atorvastatin can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Isoniazid is combined with Atorvastatin.Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Atorvastatin.Approved
ItraconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe risk or severity of adverse effects can be increased when Ivacaftor is combined with Atorvastatin.Approved
IxazomibThe serum concentration of Atorvastatin can be increased when it is combined with Ixazomib.Approved
JosamycinThe risk or severity of adverse effects can be increased when Josamycin is combined with Atorvastatin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Atorvastatin.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Atorvastatin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Atorvastatin.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Atorvastatin.Approved, Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Lansoprazole is combined with Atorvastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Atorvastatin.Approved
LapatinibThe risk or severity of adverse effects can be increased when Lapatinib is combined with Atorvastatin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atorvastatin.Approved
LepirudinThe serum concentration of Atorvastatin can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Atorvastatin.Approved, Investigational
LetaxabanThe serum concentration of Atorvastatin can be increased when it is combined with Letaxaban.Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atorvastatin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Atorvastatin.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Atorvastatin.Experimental
LinagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Atorvastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Atorvastatin.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Lomitapide is combined with Atorvastatin.Approved
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Atorvastatin.Approved
LopinavirThe serum concentration of Atorvastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Atorvastatin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Atorvastatin.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Atorvastatin.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Atorvastatin.Approved
LumacaftorThe serum concentration of Atorvastatin can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Atorvastatin.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Atorvastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Atorvastatin.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Atorvastatin.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Atorvastatin.Approved
MelagatranThe serum concentration of Atorvastatin can be increased when it is combined with Melagatran.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Mequitazine is combined with Atorvastatin.Approved
MetahexamideAtorvastatin may increase the hypoglycemic activities of Metahexamide.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Atorvastatin.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Atorvastatin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Atorvastatin.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Methimazole is combined with Atorvastatin.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atorvastatin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Atorvastatin.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Atorvastatin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Atorvastatin.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Atorvastatin.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Metyrapone is combined with Atorvastatin.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Atorvastatin.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Atorvastatin.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Atorvastatin.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.Approved, Illicit
MifepristoneThe serum concentration of Atorvastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Atorvastatin.Approved
MitotaneThe serum concentration of Atorvastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Atorvastatin.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Modafinil is combined with Atorvastatin.Approved, Investigational
MoexiprilThe serum concentration of Atorvastatin can be increased when it is combined with Moexipril.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Atorvastatin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Atorvastatin can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Atorvastatin.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atorvastatin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Atorvastatin.Approved, Withdrawn
NelfinavirThe serum concentration of Atorvastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Atorvastatin.Approved
NevirapineThe risk or severity of adverse effects can be increased when Nevirapine is combined with Atorvastatin.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Atorvastatin.Approved, Investigational, Nutraceutical
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Atorvastatin.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Atorvastatin.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Atorvastatin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Atorvastatin.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Atorvastatin.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Atorvastatin.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Atorvastatin.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Atorvastatin.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atorvastatin.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Atorvastatin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atorvastatin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Atorvastatin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Atorvastatin.Approved
NitroaspirinThe serum concentration of Atorvastatin can be increased when it is combined with Nitroaspirin.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Norfloxacin is combined with Atorvastatin.Approved
NoscapineThe risk or severity of adverse effects can be increased when Noscapine is combined with Atorvastatin.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Atorvastatin.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Atorvastatin.Vet Approved
OmapatrilatThe serum concentration of Atorvastatin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Atorvastatin can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe risk or severity of adverse effects can be increased when Omeprazole is combined with Atorvastatin.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Atorvastatin.Experimental
OsimertinibThe serum concentration of Atorvastatin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Atorvastatin can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Atorvastatin.Experimental, Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Atorvastatin.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Atorvastatin.Approved, Investigational
OxymetholoneThe risk or severity of adverse effects can be increased when Oxymetholone is combined with Atorvastatin.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atorvastatin.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Atorvastatin.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Atorvastatin.Approved
ParitaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Paritaprevir.Approved
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Atorvastatin.Approved
PentobarbitalThe metabolism of Atorvastatin can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Atorvastatin.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Atorvastatin.Approved, Investigational
PerindoprilThe serum concentration of Atorvastatin can be increased when it is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Atorvastatin.Approved
PhenindioneAtorvastatin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Atorvastatin can be increased when combined with Phenobarbital.Approved
PhenprocoumonAtorvastatin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Atorvastatin can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe risk or severity of adverse effects can be increased when Pilocarpine is combined with Atorvastatin.Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Atorvastatin.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Atorvastatin.Approved
PioglitazoneThe metabolism of Atorvastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atorvastatin.Approved
PosaconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Atorvastatin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Atorvastatin.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Atorvastatin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Atorvastatin.Withdrawn
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Atorvastatin.Approved
PrimidoneThe metabolism of Atorvastatin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Atorvastatin can be increased when it is combined with Prinomastat.Investigational
ProgesteroneThe risk or severity of adverse effects can be increased when Progesterone is combined with Atorvastatin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Atorvastatin.Approved, Investigational, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atorvastatin.Approved
QuinaprilThe serum concentration of Atorvastatin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Atorvastatin.Approved
QuinineThe serum concentration of Atorvastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Quinupristin is combined with Atorvastatin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Rabeprazole is combined with Atorvastatin.Approved, Investigational
RacecadotrilThe serum concentration of Atorvastatin can be increased when it is combined with Racecadotril.Investigational
RaloxifeneThe risk or severity of adverse effects can be increased when Raloxifene is combined with Atorvastatin.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
RamiprilThe serum concentration of Atorvastatin can be increased when it is combined with Ramipril.Approved
RanitidineThe risk or severity of adverse effects can be increased when Ranitidine is combined with Atorvastatin.Approved
RanolazineThe serum concentration of Atorvastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Atorvastatin.Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Regorafenib is combined with Atorvastatin.Approved
RemikirenThe serum concentration of Atorvastatin can be increased when it is combined with Remikiren.Approved
RepaglinideThe risk or severity of adverse effects can be increased when Repaglinide is combined with Atorvastatin.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin.Approved, Experimental, Investigational
RibociclibThe serum concentration of Atorvastatin can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Atorvastatin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Atorvastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Atorvastatin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atorvastatin.Approved, Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Rilpivirine is combined with Atorvastatin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Atorvastatin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Atorvastatin.Approved, Investigational
RitonavirThe serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Atorvastatin can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Atorvastatin.Approved, Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Atorvastatin.Approved
RosiglitazoneThe metabolism of Atorvastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Atorvastatin.Approved
RoxithromycinThe risk or severity of adverse effects can be increased when Roxithromycin is combined with Atorvastatin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Atorvastatin can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe risk or severity of adverse effects can be increased when Rutin is combined with Atorvastatin.Experimental, Investigational
S-3304The serum concentration of Atorvastatin can be increased when it is combined with S-3304.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Atorvastatin.Approved, Vet Approved
SaquinavirThe serum concentration of Atorvastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Sarilumab is combined with Atorvastatin.Approved
SaxagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Atorvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Atorvastatin.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Atorvastatin.Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Atorvastatin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.Approved
SiltuximabThe serum concentration of Atorvastatin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Atorvastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Simvastatin is combined with Atorvastatin.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Atorvastatin.Approved, Investigational
SitagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Sitaxentan is combined with Atorvastatin.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Atorvastatin can be increased when it is combined with Sivelestat.Investigational
Sodium bicarbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Atorvastatin.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Atorvastatin.Approved, Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Atorvastatin.Approved
SpiraprilThe serum concentration of Atorvastatin can be increased when it is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spironolactone.Approved
St. John's WortThe metabolism of Atorvastatin can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Atorvastatin can be increased when it is combined with Stiripentol.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Atorvastatin.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Atorvastatin.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Atorvastatin.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Atorvastatin.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Atorvastatin.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Tadalafil is combined with Atorvastatin.Approved, Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Tamoxifen is combined with Atorvastatin.Approved
TelaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Telithromycin.Approved
TemocaprilThe serum concentration of Atorvastatin can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Atorvastatin.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Atorvastatin.Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Atorvastatin.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Terfenadine is combined with Atorvastatin.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Atorvastatin.Experimental
TeriflunomideThe serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Atorvastatin.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Atorvastatin.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Testosterone is combined with Atorvastatin.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Atorvastatin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Atorvastatin.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Atorvastatin.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.Approved, Withdrawn
ThiorphanThe serum concentration of Atorvastatin can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Atorvastatin.Approved
TioclomarolAtorvastatin may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Atorvastatin.Approved
TipranavirThe serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Atorvastatin.Approved
TolazamideAtorvastatin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideAtorvastatin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Atorvastatin.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Topiroxostat is combined with Atorvastatin.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Atorvastatin.Approved, Investigational
TrabectedinAtorvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Atorvastatin.Approved, Investigational
TrandolaprilThe serum concentration of Atorvastatin can be increased when it is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Atorvastatin.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atorvastatin.Approved
TrimethoprimThe metabolism of Atorvastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Troglitazone is combined with Atorvastatin.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Troleandomycin is combined with Atorvastatin.Approved
TromethamineThe serum concentration of Atorvastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Atorvastatin.Vet Approved
UbenimexThe serum concentration of Atorvastatin can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Atorvastatin.Approved, Investigational, Nutraceutical
UlinastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Atorvastatin.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Atorvastatin.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Atorvastatin.Approved
VildagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Atorvastatin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atorvastatin.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Atorvastatin.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Atorvastatin.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Atorvastatin.Investigational
VoriconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAtorvastatin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Atorvastatin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Atorvastatin.Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Atorvastatin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Zafirlukast is combined with Atorvastatin.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Atorvastatin.Approved
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Atorvastatin.Approved
ZofenoprilThe serum concentration of Atorvastatin can be increased when it is combined with Zofenopril.Experimental
ZucapsaicinThe risk or severity of adverse effects can be increased when Zucapsaicin is combined with Atorvastatin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can significantly increase serum levels of this product.
  • Food may decrease maximum plasma levels and area under the curve, but this is clinically inconsequential according to the manufacturer.
  • Take with low fat meal.

References

Synthesis Reference

Zlatko Pflaum, "Process for the preparation of amorphous atorvastatin." U.S. Patent US20020183527, issued December 05, 2002.

US20020183527
General References
  1. Rouleau J: Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med. 2005 Dec;118 Suppl 12A:28-35. [PubMed:16356805]
  2. Maggon K: Best-selling human medicines 2002-2004. Drug Discov Today. 2005 Jun 1;10(11):739-42. [PubMed:15922927]
External Links
Human Metabolome Database
HMDB05006
KEGG Drug
D07474
KEGG Compound
C06834
PubChem Compound
60823
PubChem Substance
46506188
ChemSpider
54810
BindingDB
22164
ChEBI
39548
ChEMBL
CHEMBL1487
Therapeutic Targets Database
DAP000553
PharmGKB
PA448500
HET
117
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Atorvastatin
ATC Codes
C10AA05 — AtorvastatinC10BX06 — Atorvastatin, acetylsalicylic acid and ramiprilC10BA05 — Atorvastatin and ezetimibeC10BX03 — Atorvastatin and amlodipineC10BX11 — Atorvastatin, amlodipine and perindoprilC10BX08 — Atorvastatin and acetylsalicylic acid
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
PDB Entries
1hwk
FDA label
Download (62 KB)
MSDS
Download (57.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic ScienceObstructive Sleep Apnea of Adult1
0RecruitingTreatmentCancer of Breast / Cancer, Breast / Tumors, Breast1
0RecruitingTreatmentEndometrial Cancers1
0Unknown StatusPreventionStroke, Ischemic / Ventilator-Associated Pneumonia (VAP)1
1Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction (MI) / Reperfusion Injury1
1Active Not RecruitingTreatmentHealthy Male Subjects1
1CompletedNot AvailableAcute Coronary Syndromes (ACS)1
1CompletedNot AvailableEffect of Atorvastatin on the Pharmacokinetics of Lomitapide1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHigh Blood Pressure (Hypertension)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Hypercholesterolaemia1
1CompletedNot AvailableHypercholesterolaemia3
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailablePediatric Heterozygous Hypercholesterolemia1
1CompletedBasic ScienceCoronary Heart Disease (CHD)1
1CompletedBasic ScienceDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedBasic ScienceDyslipidemias1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHypercholesterolaemia1
1CompletedDiagnosticBone destruction / Osteoarthritis (OA)1
1CompletedHealth Services ResearchHealthy Controls1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionAtypical Ductal Breast Hyperplasia / Cancer, Breast / Ductal Breast Carcinoma In Situ / Lobular Breast Carcinoma In Situ1
1CompletedTreatmentAcute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjögren's Syndrome1
1CompletedTreatmentAtherosclerotic Vascular Diseases1
1CompletedTreatmentAutoimmune Diseases / Disseminated or Multiple Sclerosis Nos / Disseminated Sclerosis / Multiple Sclerosis, Acute Relapsing / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Primary Progressive1
1CompletedTreatmentCholesterol, LDL / Hypercholesterolaemia1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentDiseases of the Circulatory System / Hypertension,Essential1
1CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemia (Fredrickson Type Ⅱb)1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentEnd-Stage Kidney Disease1
1CompletedTreatmentEndometriosis / Prostate Cancer1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers18
1CompletedTreatmentHealthy Volunteers / Normocholesterolaemic Men / Normozoospermic Men1
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHyperlipidemias1
1CompletedTreatmentHyperlipidemias / Hypertension,Essential2
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSleep disorders and disturbances1
1Not Yet RecruitingNot AvailableHealthy Male Subjects1
1Not Yet RecruitingTreatmentImpaired Renal Function1
1RecruitingTreatmentDyslipidemias1
1RecruitingTreatmentHypertension, Hyperlipidemia1
1TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
1Unknown StatusTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPlasma Cell Myeloma1
1Unknown StatusTreatmentStrokes1
1WithdrawnBasic ScienceAdvanced Adenocarcinoma of the Colon or Rectum1
1, 2CompletedTreatmentMetabolic Syndromes1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Not Yet RecruitingBasic ScienceSleep Apnea, Obstructive1
1, 2Not Yet RecruitingPreventionPrimary Arteriovenous Fistula Failure1
1, 2Not Yet RecruitingTreatmentCerebral Cavernous Malformations1
1, 2Not Yet RecruitingTreatmentEbola Virus Disease1
1, 2RecruitingTreatmentMucocutaneous Lymph Node Syndrome1
1, 2RecruitingTreatmentNon-segmental Vitiligo1
1, 2RecruitingTreatmentVenous Thromboembolism1
1, 2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
1, 2Unknown StatusTreatmentMetabolic Syndromes1
1, 2Unknown StatusTreatmentStenosis1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Hyperlipidemias1
2Active Not RecruitingPreventionProstatic Neoplasms1
2Active Not RecruitingTreatmentNonalcoholic Steatohepatitis1
2Active Not RecruitingTreatmentSpastic Paraplegia, Hereditary1
2Active Not RecruitingTreatmentVitiligo1
2CompletedBasic ScienceHuman Immunodeficiency Virus (HIV)1
2CompletedDiagnosticHealthy Volunteers1
2CompletedPreventionAlzheimer's Disease (AD)1
2CompletedPreventionDisseminated Sclerosis1
2CompletedPreventionHip Fractures / Inflammatory Reaction / Myocardial Ischemia1
2CompletedPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2CompletedPreventionMetabolic Syndromes1
2CompletedSupportive CareNeoplasms, Malignant1
2CompletedTreatmentALL, Childhood / Cardiovascular Disease (CVD) / Childhood NHL1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Smoking1
2CompletedTreatmentCancer, Breast / One to five years postmenopausal1
2CompletedTreatmentCardiovascular Disease (CVD)1
2CompletedTreatmentCardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Renal Dysfunction1
2CompletedTreatmentCardiovascular Disease (CVD) / Renal Dysfunction2
2CompletedTreatmentCarotid Atherosclerosis1
2CompletedTreatmentChronic Hepatitis C Infection1
2CompletedTreatmentChronic Subdural Hematomas1
2CompletedTreatmentCrohns Disease1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes Mellitus (DM) / Hypercholesterolaemia / Metabolic Syndromes1
2CompletedTreatmentDiabetes Mellitus (DM) / Ulcus Cruris1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentDyslipidemias8
2CompletedTreatmentGlioblastoma Multiforme1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHigh Cholesterol1
2CompletedTreatmentHypercholesterolaemia11
2CompletedTreatmentHypercholesterolaemia / Hyperlipidemias / Muscle Soreness1
2CompletedTreatmentHyperlipidemias5
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentLeukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentPlatelets Dysfunction1
2CompletedTreatmentPolycystic Ovaries Syndrome1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSarcoidosis, Pulmonary1
2CompletedTreatmentVascular Diseases1
2Enrolling by InvitationTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction (MI) / Transplantation, Stem Cell1
2Enrolling by InvitationTreatmentSickle Cell Disorders / Sickle Cell Nephropathy1
2Not Yet RecruitingPreventionCancers / Cardiotoxicity / Heart Failure, Unspecified1
2Not Yet RecruitingTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction (MI) / Transplantation, Stem Cell1
2Not Yet RecruitingTreatmentChronic Subdural Hematomas1
2Not Yet RecruitingTreatmentClinical Outcome Improvement1
2Not Yet RecruitingTreatmentDyslipidemias1
2Not Yet RecruitingTreatmentNeoplasms, Breast1
2Not Yet RecruitingTreatmentProstate Cancer1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Aggressive Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionCancer, Breast1
2RecruitingPreventionCoronary Artery Disease1
2RecruitingTreatmentBipolar Disorder (BD) / Lithium Use, Nephrogenic Diabetes Insipidus1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancer, Breast / Cardiotoxicity / Heart Diseases / Myocardial Dysfunction1
2RecruitingTreatmentFlu caused by Influenza1
2RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2RecruitingTreatmentNon-Alcoholic Steatohepatitis1
2RecruitingTreatmentScleroderma1
2SuspendedPreventionNasopharyngeal Carcinoma / Radiation Therapy Complication1
2TerminatedBasic ScienceCoronary Artery Disease / Dyslipidemias1
2TerminatedPreventionAvascular Necrosis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentGlomerulonephritis minimal lesion / Hyperlipidemias1
2TerminatedTreatmentHypercholesterolaemia / Venous Thromboembolism1
2TerminatedTreatmentMild Traumatic Brain Injury (MTBI) / Post-Traumatic Stress Disorder (PTSD) / Traumatic Brain Injury (TBI)1
2TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
2Unknown StatusPreventionAcute Non-ST-segment Elevation Myocardial Infarction / Stable Angina (SA) / Unstable Angina (UA)1
2Unknown StatusPreventionCancer, Breast1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusPreventionProstatic Neoplasms1
2Unknown StatusSupportive CareAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2Unknown StatusTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2, 3CompletedPreventionMyocardial Infarction (MI) / Renal Failure / Strokes1
2, 3CompletedPreventionProphylaxis of Contrast-induced nephropathy1
2, 3CompletedTreatmentAcute Kidney Dysfunction1
2, 3CompletedTreatmentArterial Occlusive Diseases / Insulin Resistance / Intermittent Claudication1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3CompletedTreatmentChronic Periodontitis4
2, 3CompletedTreatmentDyslipidemias1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / High Blood Pressure (Hypertension) / Subjective Cognitive Decline1
2, 3RecruitingTreatmentHyperlipidemias1
2, 3TerminatedTreatmentAdvanced Cancers1
2, 3Unknown StatusTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3WithdrawnTreatmentHIV-infection/Aids / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3Active Not RecruitingTreatmentCoronary Artery Disease1
3Active Not RecruitingTreatmentDiabetes, Hyperlipidemia, Mixed Dyslipidemia1
3Active Not RecruitingTreatmentHypercholesterolaemia2
3Active Not RecruitingTreatmentImpaired Renal Function1
3CompletedPreventionAcute Coronary Syndromes (ACS)1
3CompletedPreventionAortic Aneurism / Myocardial Infarction (MI) / Peripheral Vascular Disease (PVD)1
3CompletedPreventionCoronary Artery Disease1
3CompletedPreventionDiabetes, Diabetes Mellitus Type 11
3CompletedPreventionHeart Valve Diseases1
3CompletedPreventionProphylaxis of preeclampsia1
3CompletedTreatmentAcute Coronary Syndromes (ACS)2
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAssess the Periprocedural Myocardial Necrosis1
3CompletedTreatmentAtherosclerosis3
3CompletedTreatmentAtherosclerosis / Calcifications, Vascular / Dyslipidemias / Inflammatory Reaction1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAtherosclerosis / Coronary Artery Disease / Hypercholesterolaemia1
3CompletedTreatmentAtherosclerotic Disease / Coronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias / Insulin Resistance1
3CompletedTreatmentCardiovascular Disorder / Diabetes Mellitus (DM)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentCombined (Atherogenic) Dyslipidemia / Coronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentCoronary Arteriosclerosis / Coronary Heart Disease (CHD) / Hyperlipidemias1
3CompletedTreatmentCoronary Artery Atherosclerosis1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia2
3CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentDiabetes Mellitus, Insulin-Dependent / Hypercholesterolaemia1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia3
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolemia, Familial1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus2
3CompletedTreatmentHeterozygous Familial Hypercholesterolemia1
3CompletedTreatmentHypercholesterolaemia26
3CompletedTreatmentHypercholesterolaemia / Metabolic Syndromes1
3CompletedTreatmentHypercholesterolaemia / Primary Biliary Cirrhosis (PBC)1
3CompletedTreatmentHypercholesterolaemia / Type 2 Diabetes Mellitus1
3CompletedTreatmentHypercholesterolemia, Familial2
3CompletedTreatmentHypercholesterolemia, Familial / Hyperlipidemias2
3CompletedTreatmentHypercholesterolemia, Familial / Mixed hypercholesterolemia1
3CompletedTreatmentHyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events1
3CompletedTreatmentHyperlipidemias9
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHyperlipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentHyperlipoproteinemia Type iv / Hypertriglyceridemias1
3CompletedTreatmentHypertriglyceridemias1
3CompletedTreatmentHypertrophic Cardiomyopathy1
3CompletedTreatmentImpaired Renal Function1
3CompletedTreatmentLupus Erythematosus, Systemic1
3CompletedTreatmentMetabolic Syndromes1
3CompletedTreatmentPrimary Hyperlipidemia and Mixed Dyslipidemia1
3CompletedTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentMixed hypercholesterolemia2
3Not Yet RecruitingPreventionMyocardial Oedema1
3Not Yet RecruitingTreatmentEssential Hypertension, Dyslipidemia1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3RecruitingPreventionCardiovascular Disease (CVD) / Coronary Artery Disease / Type 2 Diabetes Mellitus1
3RecruitingPreventionCarotid Artery Stenosis / Strokes1
3RecruitingTreatmentAortic Valve Stenosis / Ventricular Hypertrophy1
3RecruitingTreatmentAtherosclerosis / Dyslipidemias1
3RecruitingTreatmentBicuspid Aortic Valve (BAV)1
3RecruitingTreatmentCancers / Overall Survival / Quality of Life1
3RecruitingTreatmentCombined Dyslipidemia1
3RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHypercholesterolaemia1
3TerminatedPreventionInflammatory Reaction / Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
3TerminatedTreatmentCardiovascular Disease (CVD)1
3TerminatedTreatmentCoronary Artery Disease / High Cholesterol1
3TerminatedTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
3TerminatedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3TerminatedTreatmentDyslipidemias / Hyperlipidemias1
3TerminatedTreatmentHypercholesterolaemia5
3TerminatedTreatmentHyperlipidemias1
3TerminatedTreatmentHyperlipoproteinemia Type III1
3TerminatedTreatmentStable Coronary Artery Disease Undergoing PCI1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentMixed hypercholesterolemia1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentAbdominal Surgeries1
3Unknown StatusTreatmentBranch Retinal Vein Occlusion / Central Retinal Vein Occlusion (CRVO) / Retinal Vein Occlusions(RVO) / Retinal Vein Thrombosis / Thrombosis1
3Unknown StatusTreatmentCoronary Angioplasty / Coronary Artery Disease1
3Unknown StatusTreatmentHyperlipidemia, Familial Combined1
3Unknown StatusTreatmentHyperlipidemias1
3Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
3Unknown StatusTreatmentStable Coronary Artery Disease1
3Unknown StatusTreatmentMixed hypercholesterolemia1
3WithdrawnTreatmentHypertriglyceridemias1
3WithdrawnTreatmentPsoriasis1
4Active Not RecruitingNot AvailableAtherosclerosis / Carotid Artery Diseases / Coronary Artery Disease1
4Active Not RecruitingBasic ScienceDrug intolerance1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS)1
4Active Not RecruitingTreatmentAging-related Inflammation in HIV-infected Patients1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentHIV Dementia2
4Active Not RecruitingTreatmentHypercholesterolaemia / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentStroke, Ischemic1
4CompletedNot AvailableAbdominal Aortic Aneurysms (AAA)1
4CompletedNot AvailableCardiovascular Disease (CVD) / Cholesterol, LDL / Cognition / Type 2 Diabetes Mellitus1
4CompletedNot AvailableDyslipidemias / Vascular Diseases1
4CompletedNot AvailableHealthy Volunteers3
4CompletedNot AvailableHypercholesterolaemia4
4CompletedNot AvailablePrediabetic State1
4CompletedBasic ScienceAtherosclerosis / Coronary Artery Disease / Endothelial Dysfunction / HMG-CoA Reductase Inhibitor Toxicity / Oxidative Stress1
4CompletedBasic ScienceBone destruction / Hypercholesterolaemia1
4CompletedBasic ScienceHyperlipidemias / Metabolic Syndromes / Renal Failure Chronic Requiring Hemodialysis / Type 2 Diabetes Mellitus1
4CompletedBasic SciencePeripheral Arterial Disease (PAD)1
4CompletedDiagnosticMuscular Diseases1
4CompletedDiagnosticMyopathies1
4CompletedDiagnosticMyotoxicity of Atorvastatin Treatment1
4CompletedPreventionAcute Coronary Syndromes (ACS)2
4CompletedPreventionAcute Kidney Injury (AKI) / Aortic Surgery1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiac Insufficiency Following Cardiac Surgery / Disorder; Heart, Functional, Postoperative, Cardiac Surgery / Ischaemia-reperfusion Injury / Nonvalvular Atrial Fibrillation1
4CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Accidents / Coronary Heart Disease (CHD)1
4CompletedPreventionCerebrovascular Accidents / Coronary Artery Bypass Graft / Major Coronary Event / Revascularization / Unstable Angina (UA)1
4CompletedPreventionContrast Induced Nephropathy (CIN)1
4CompletedPreventionCoronary Artery Bypass Grafting (CABG) Surgery1
4CompletedPreventionEndothelial Dysfunction / Ischemia Reperfusion Injury1
4CompletedPreventionHemostasis / Inflammatory Reaction / Magnetic Resonance Imaging (MRI) / Neuropsychology / Nonvalvular Atrial Fibrillation1
4CompletedPreventionMyocardial Infarction (MI)1
4CompletedPreventionSystemic Lupus Erythematosus (SLE)1
4CompletedPreventionType 2 Diabetes Mellitus1
4CompletedScreeningInflammatory Reaction1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Dyslipidemias1
4CompletedTreatmentAcute Myocardial Infarction (AMI)2
4CompletedTreatmentAngina Pectoris / High Blood Pressure (Hypertension) / Hypercholesterolaemia1
4CompletedTreatmentAnginal Pain1
4CompletedTreatmentAngioplasty / Myocardial Infarction (MI) / Percutaneous Coronary1
4CompletedTreatmentArrythmias1
4CompletedTreatmentArrythmias / Endothelial Dysfunction / Inflammatory Reaction / Nonvalvular Atrial Fibrillation1
4CompletedTreatmentArteriosclerosis / Calcinosis / Hyperparathyroidism, Secondary1
4CompletedTreatmentAtherosclerosis1
4CompletedTreatmentAtherosclerosis / Coronary Artery Disease1
4CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Dyslipidemias / Strokes1
4CompletedTreatmentAtherosclerosis / Hypercholesterolaemia1
4CompletedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Hypertriglyceridemias / Lipid Disorders1
4CompletedTreatmentBronchiectasis2
4CompletedTreatmentCVD1
4CompletedTreatmentCardiovascular Disease (CVD)2
4CompletedTreatmentCardiovascular Disease (CVD) / Dyslipidemias / Hypercholesterolaemia1
4CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocardial Diseases / Myocardial Ischemia / Prophylaxis of cardiomyopathy1
4CompletedTreatmentCardiovascular Disease (CVD) / Ischemia Reperfusion Injury1
4CompletedTreatmentCerebrovascular Accidents / Coronary Arteriosclerosis / Dyslipidemias / Peripheral Vascular Disease (PVD) / Type 2 Diabetes Mellitus2
4CompletedTreatmentCerebrovascular Accidents / Hypercholesterolaemia1
4CompletedTreatmentChronic Hepatitis C Infection1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentChronic Periaortitis / Intrabony Periodontal Defect1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCoronary Arteriosclerosis / Hypercholesterolaemia2
4CompletedTreatmentCoronary Artery Bypass Surgery / Elective Surgical Procedure1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / Hypercholesterolaemia3
4CompletedTreatmentCoronary Artery Disease / Hyperlipidemias1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia2
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Dyslipidemias1
4CompletedTreatmentDyslipidemias7
4CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)3
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hypercholesterolaemia1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Stable Chronic Kidney Disease1
4CompletedTreatmentHypercholesterolaemia10
4CompletedTreatmentHypercholesterolemia With Type2DM1
4CompletedTreatmentHypercholesterolemia, Familial1
4CompletedTreatmentHyperlipidemias1
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentMulti-vessel Diseases, Angina1
4CompletedTreatmentMyocardial Infarction (MI) / Reperfusion Injury1
4CompletedTreatmentChronic, stable Angina pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentStable Angina (SA)1
4CompletedTreatmentStroke, Ischemic1
4CompletedTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4CompletedTreatmentVascular Surgery1
4CompletedTreatmentTransient ischemia attacks1
4Enrolling by InvitationPreventionDisability Free Survival / Elderly / Healthy Volunteers / Independent Living1
4Enrolling by InvitationTreatmentCerebral Infarctions / CLOPIDOGREL, POOR METABOLISM of (Disorder)1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Not Yet RecruitingDiagnosticCoronary Artery Disease1
4Not Yet RecruitingPreventionCardiovascular Disease (CVD)2
4Not Yet RecruitingPreventionMitochondrial Diseases1
4Not Yet RecruitingTreatmentArterial Hypertension / Blood Pressures / Dyslipidemias / Lipid Metabolism Disorders1
4Not Yet RecruitingTreatmentCarotid Artery Stenosis1
4Not Yet RecruitingTreatmentCoronary Artery Disease2
4RecruitingDiagnosticHyperlipidemias1
4RecruitingOtherCardiovascular Disease (CVD)1
4RecruitingPreventionAcute Coronary Syndromes (ACS)1
4RecruitingPreventionAdverse Effects / Cardiovascular Disease (CVD) / Hyperlipidemias1
4RecruitingPreventionArrythmias1
4RecruitingPreventionCardiothoracic Surgery / Post-Operative Atrial Fibrillation1
4RecruitingPreventionCoronary Artery Disease1
4RecruitingPreventionHepatocellular,Carcinoma1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypercholesterolaemia1
4RecruitingTreatmentCardiovascular Disease (CVD)1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDental Plaque1
4RecruitingTreatmentDiabetes Mellitus (DM) / Dyslipidemias / Fatty Liver1
4RecruitingTreatmentDiabetes Mellitus Type 2 Platelets Reactivity Statin1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentMyocardial Infarction (MI)1
4RecruitingTreatmentSevere Hypercholesterolemia1
4RecruitingTreatmentSocket Preservation1
4RecruitingTreatmentType 2 Diabetes Mellitus1
4TerminatedNot AvailableHypertension and Cardiovascular Risk Factors1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedDiagnosticMyopathic Conditions1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionCardiovascular Disease (CVD) / Osteoarthritis (OA)1
4TerminatedPreventionCoarctation of the Aorta1
4TerminatedPreventionHigh Blood Pressure (Hypertension)1
4TerminatedTreatmentAortic Valve Stenosis1
4TerminatedTreatmentAtherosclerosis / Coronary Artery Disease / Hypercholesterolaemia1
4TerminatedTreatmentChronic Kidney Disease (CKD) / High Cholesterol1
4TerminatedTreatmentHypercholesterolaemia1
4TerminatedTreatmentHyperlipidemias / Non-Insulin Dependent Diabetes Mellitus / Type 2 Diabetes Mellitus1
4TerminatedTreatmentStable Angina (SA)1
4Unknown StatusNot AvailableCoronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Non-Coronary Atherosclerotic Disease1
4Unknown StatusNot AvailableDyslipidemia in Patients With Diabetes Mellitus1
4Unknown StatusPreventionCarotid Stenosis1
4Unknown StatusPreventionCholesterol, HDL1
4Unknown StatusPreventionCoronary Heart Disease (CHD)1
4Unknown StatusPreventionEndothelium / Hydroxymethylglutaryl-CoA Reductase Inhibitors1
4Unknown StatusPreventionGeneral Surgery / Prevention / Thrombosis1
4Unknown StatusPreventionVaccination Failure / Viral Hepatitis B1
4Unknown StatusTreatmentAcute Anterior Myocardial Infarction1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentAngina Pectoris, Variant1
4Unknown StatusTreatmentAngina, Prinzmetal's1
4Unknown StatusTreatmentArterial and Arteriolar Disorders1
4Unknown StatusTreatmentAtherosclerosis1
4Unknown StatusTreatmentAtherosclerosis / Inflammatory Reaction1
4Unknown StatusTreatmentCoronary Artery Disease3
4Unknown StatusTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusTreatmentDiabetes Mellitus, Hypercholessterolemia1
4Unknown StatusTreatmentDrug-eluting Stent (DES)1
4Unknown StatusTreatmentFocus of Study1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
4Unknown StatusTreatmentMyocardial Infarction (MI) / Unstable Angina (UA)1
4Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
4Unknown StatusTreatmentType 2 Diabetes Mellitus Without Insulin Treatment1
4WithdrawnTreatmentAngina Pectoris, Variant / Statins, HMG-CoA1
4WithdrawnTreatmentAtherosclerosis1
Not AvailableActive Not RecruitingTreatmentRheumatoid Arthritis1
Not AvailableCompletedNot AvailableAngina Pectoris / High Blood Pressure (Hypertension) / Hypercholesterolaemia / Hypercholesterolemia, Familial1
Not AvailableCompletedNot AvailableAtheroma / Atherosclerosis / Atherosclerotic Carotid Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Artery Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCarotid Atherosclerosis / Metabolic Syndromes / Strokes / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCongestive Cardiomyopathy1
Not AvailableCompletedNot AvailableEndothelial Function / Infection NOS / Inflammatory Reaction1
Not AvailableCompletedNot AvailableGynecologic Oncological Pelvic/Abdominal Surgery1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHydroxymethylglutaryl-CoA Reductase Inhibitors / Muscular Diseases1
Not AvailableCompletedNot AvailableHypercholesterolaemia3
Not AvailableCompletedBasic ScienceDifference of 12-hour AUC1
Not AvailableCompletedBasic ScienceHydroxymethylglutaryl-CoA Reductase Inhibitors / Type 2 Diabetes Mellitus1
Not AvailableCompletedDiagnosticCoronary Artery Disease / Hypercholesterolaemia / Monocyte Function1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI) / Acute Renal Failure (ARF) / Delirium / Icu Delirium / Post-Operative Delirium1
Not AvailableCompletedPreventionArrythmias1
Not AvailableCompletedPreventionCoronary Artery Bypass Graft1
Not AvailableCompletedPreventionBone destruction1
Not AvailableCompletedTreatmentAngioplasty, Transluminal, Percutaneous Coronary1
Not AvailableCompletedTreatmentAtherosclerosis1
Not AvailableCompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Inflammatory Reaction / Statins, HMG-CoA1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Proteinuria1
Not AvailableCompletedTreatmentCoronary Arteriosclerosis / Genetic Diseases, Inborn / Hypoalphalipoproteinemias1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentDiastolic Heart Failure1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentHealthy Volunteers2
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Hypercholesterolaemia1
Not AvailableCompletedTreatmentHypercholesterolemia With Concomitant Type 2 Diabetes1
Not AvailableCompletedTreatmentHyperlipidemias1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentShock, Septic1
Not AvailableCompletedTreatmentThoracic Surgery1
Not AvailableRecruitingBasic ScienceAtherosclerosis / Cardiovascular Disease (CVD)1
Not AvailableRecruitingBasic ScienceHyperlipidemias1
Not AvailableRecruitingTreatmentGlomerulonephritis minimal lesion1
Not AvailableRecruitingTreatmentSleep Deprivation1
Not AvailableTerminatedBasic ScienceDiabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableTerminatedPreventionRenal Dysfunction1
Not AvailableTerminatedTreatmentCoronary Artery Disease1
Not AvailableTerminatedTreatmentDiastolic Heart Failure1
Not AvailableUnknown StatusNot AvailableDisseminated Sclerosis1
Not AvailableUnknown StatusBasic ScienceAutonomic Changes of Cardiomyocytes Repolarisation / Heterogeneity of Cardiomyocytes Repolarisation1
Not AvailableUnknown StatusDiagnosticDiabetes Mellitus (DM)1
Not AvailableUnknown StatusDiagnosticPeripheral Arterial Disease (PAD)1
Not AvailableUnknown StatusPreventionAtherosclerosis1
Not AvailableUnknown StatusPreventionCoronary Heart Disease (CHD)1
Not AvailableUnknown StatusPreventionInflammatory Reaction / Myocardial Infarction (MI) / Myocardial Ischemia1
Not AvailableUnknown StatusTreatmentAcute Coronary Syndromes (ACS)2
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentCongestive Heart Failure (CHF)1
Not AvailableUnknown StatusTreatmentCoronary Artery1
Not AvailableUnknown StatusTreatmentEndometriosis / Pain1
Not AvailableUnknown StatusTreatmentHypercholesterolaemia / Thrombosis1
Not AvailableUnknown StatusTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
Not AvailableUnknown StatusTreatmentMixed hypercholesterolemia1
Not AvailableWithdrawnBasic ScienceNeurocognitive Dysfunction1
Not AvailableWithdrawnTreatmentAtherosclerosis / Type 2 Diabetes Mellitus1
Not AvailableWithdrawnTreatmentComplication of Renal Dialysis1
Not AvailableWithdrawnTreatmentEndothelial Dysfunction1
Not AvailableWithdrawnTreatmentNon Alcoholic Fatty Liver Diseases (NAFLD)1
Not AvailableWithdrawnTreatmentRecurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral20 mg/301
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/301
Tablet, film coatedOral80 mg/1
TabletOral
Tablet, film coatedOral
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Lipitor 20 mg tablet5.0USD tablet
Lipitor 40 mg tablet5.0USD tablet
Lipitor 80 mg tablet5.0USD tablet
Lipitor 10 mg tablet3.5USD tablet
Lipitor 40 mg Tablet2.52USD tablet
Lipitor 80 mg Tablet2.52USD tablet
Lipitor 20 mg Tablet2.34USD tablet
Lipitor 10 mg Tablet1.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4681893No1992-09-242009-09-24Us
CA2521776No2006-04-252022-05-21Canada
CA2220018No2001-04-172016-07-08Canada
US5969156Yes1997-01-082017-01-08Us
USRE42461Yes1997-04-252017-04-25Us
US6455574No1998-08-112018-08-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)159.2-160.7 °CNot Available
water solubilitySodium salt soluble in water, 20.4 ug/mL (pH 2.1), 1.23 mg/mL (pH 6.0)Not Available
logP5.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00063 mg/mLALOGPS
logP4.24ALOGPS
logP5.39ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area111.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity158.2 m3·mol-1ChemAxon
Polarizability59.39 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8947
Blood Brain Barrier-0.7825
Caco-2 permeable-0.8956
P-glycoprotein substrateSubstrate0.5246
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8724
Renal organic cation transporterNon-inhibitor0.8131
CYP450 2C9 substrateNon-substrate0.7887
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6841
CYP450 1A2 substrateNon-inhibitor0.8551
CYP450 2C9 inhibitorNon-inhibitor0.719
CYP450 2D6 inhibitorNon-inhibitor0.9042
CYP450 2C19 inhibitorNon-inhibitor0.6191
CYP450 3A4 inhibitorNon-inhibitor0.6675
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6894
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.5686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9904
hERG inhibition (predictor II)Non-inhibitor0.5101
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-ae5c999b091a2bc93933
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000190000-dd563e18b1f0f74aadd5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0zfs-0007960000-cb66a18d2f0a687261ba
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-002b-0059000000-0942bc1e35434cd7d0d3
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0093000000-f42ba46820a3cf3295c5
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udj-0005910000-b09ba5f3b86948c7f3cb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0000090000-6f297ca79ae1761aac33
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-1009300000-9479520f395dcdd585e7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0092000000-9b561b8d35c3bdc5e46a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-3aad87273e7f9942a50f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01t9-1090000000-3f0efff41ebdb5320ce4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-2090000000-0227638704b90c4249d0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0000090000-65c729c6734f6533c431
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-1009300000-9122e4479d8c0c32bb0d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0092000000-22d639a8882509e1bcdb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-30a0198165bae85fa258
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01t9-1090000000-cb3feea45f5280f05c37
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-2090000000-8db2f70b373277f143c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udj-0005910000-a63c845ca248d958068d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6s-1085190000-9e43612012842effca5a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0031900000-4081fba1ae61b0d871cf
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052f-0000980000-6751fefdee0a257e52f8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0000900000-4009a70e947dcceb6e0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0085900000-e1a4447e4c9a4bda83b2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0092100000-4a5517154ad5f7375ea2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-e741fcb91eb29d1032cb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-0000900000-fdd41dae94afd3f4d3c5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000490000-25199beeece682c7de9e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0020900000-71cacdfc979c4386762b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0092000000-38374b1412250df34777
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-87710909ebad67c88f3b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0190000000-60e7ef3dc3f76db11c5f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f72-0290000000-e8c2cda8588874b2aaa5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000490000-a5ee6b466e73e9e72383
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0011900000-b8fc562d4be5ffb07f59
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0092000000-df78998b01951a3dd03a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-19c391db652668c97d59
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0190000000-931a1911dcd7ec9dbbc8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f72-0290000000-6157ef91cb98aeef5cf7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-0000900000-cd6fb2c00146543cbb47
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6x-0092420000-fb2c084ecdd5af8f6f7b

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylpyrroles. These are aromatic heterocyclic compounds with a structure based on a pyrrole ring linked to exactly two phenyl groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrroles
Sub Class
Substituted pyrroles
Direct Parent
Diphenylpyrroles
Alternative Parents
Aromatic anilides / Medium-chain hydroxy acids and derivatives / Pyrrole carboxamides / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Fluorobenzenes / Halogenated fatty acids / Hydroxy fatty acids / Heterocyclic fatty acids / Aryl fluorides
show 13 more
Substituents
2,3-diphenylpyrrole / Aromatic anilide / Medium-chain hydroxy acid / Pyrrole-3-carboxamide / Pyrrole-3-carboxylic acid or derivatives / Medium-chain fatty acid / Beta-hydroxy acid / Fluorobenzene / Halobenzene / Halogenated fatty acid
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
statin (synthetic), aromatic amide, pyrroles, dihydroxy monocarboxylic acid, monofluorobenzenes (CHEBI:39548)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Davidson MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Mar;11(3):125-41. [PubMed:12769127]
  2. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M: Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):123-6. [PubMed:12808485]
  3. Baxter JD, Webb P, Grover G, Scanlan TS: Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004 May-Jun;15(4):154-7. [PubMed:15109613]
  4. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004 Nov 12;324(2):835-9. [PubMed:15474503]
  5. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M: Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005 Mar;92(6):1386-98. [PubMed:15748157]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by bindi...
Gene Name
DPP4
Uniprot ID
P27487
Uniprot Name
Dipeptidyl peptidase 4
Molecular Weight
88277.935 Da
References
  1. Taldone T, Zito SW, Talele TT: Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84. Epub 2007 Dec 3. [PubMed:18068977]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [PubMed:17327465]
  2. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM: Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. [PubMed:23703578]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6. [PubMed:11474784]
  2. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  2. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20. [PubMed:17178262]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Klatt S, Fromm MF, Konig J: The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6. [PubMed:23121773]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH: Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20. [PubMed:22186618]

Drug created on June 13, 2005 07:24 / Updated on December 11, 2017 13:04